Astera Labs, Inc. director Craig H. Barratt acquired 68 restricted stock units (RSUs) on October 1, 2026, in lieu of cash compensation for quarterly non-employee director retainer fees, pursuant to his election. His reported direct position after the award was 6,893 shares. The RSUs vest 100% on the three-month anniversary of August 15, 2026, subject to continuous service through the vesting date; each RSU is a contingent right to receive one common share.
Astera Labs, Inc. director Michael E. Hurlston was granted 72 restricted stock units on October 1, 2026, in lieu of cash compensation for quarterly non-employee director retainer fees, pursuant to his election. The RSUs provide for 100% vesting on the three-month anniversary of August 15, 2026, subject to continuous service through that date. Each RSU represents a contingent right to one common share. His reported post-transaction holdings were 92,554 shares, including deferred stock units and dividend equivalent units.
Astera Labs, Inc. director Stefan A. Dyckerhoff reported sales of 12,499 shares of common stock on October 7, 2026, at $376.06 per share: 3,505 shares held directly, 8,333 held by a trust of which he is trustee, and 661 held by a limited partnership whose general partner is a trust of which he is trustee. The sales were made under a Rule 10b5-1 trading plan adopted December 1, 2025. On October 1, he was granted 68 restricted stock units in lieu of cash compensation for quarterly non-employee director retainer fees. They vest 100% on the three-month anniversary of the August 15, 2026 Vesting Commencement Date, subject to his continuous service relationship through the applicable vesting date.
Astera Labs, Inc. (ALAB) is the issuer named in an affiliate notice for Stefan A. Dyckerhoff, who proposes to sell 12,499 common shares through Stifel Nicolaus & Company Inc. on NASDAQ on October 7, 2026, with an aggregate market value of $4,700,373.00. The notice lists earlier sales of 12,499 shares on August 6 and September 2, 2026, for gross proceeds of $3,897,584.00 and $3,436,755.00, respectively.
Astera Labs, Inc. is the issuer of the common stock for which FMR LLC and Abigail P. Johnson each reported beneficial ownership of 15,774,196.20 shares, or 9.1%, as of September 30, 2026. FMR LLC reported sole voting power over 15,199,893.48 shares and sole dispositive power over 15,774,196.20 shares. Abigail P. Johnson reported no voting power and sole dispositive power over 15,774,196.20 shares.
Astera Labs, Inc. (ALAB) director Stefan A. Dyckerhoff reported selling a total of 12,499 shares of common stock on September 2, 2026, in open-market transactions at weighted average prices between about $273 and $277 per share. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 1, 2025. Portions of the shares were held directly, while others were held indirectly through a trust and a limited partnership, and certain indirect positions and irrevocable trusts are reported with the filer disclaiming beneficial ownership except for his pecuniary interest.
Astera Labs, Inc. (ALAB) director Manuel Alba reported that entities associated with him sold a total of 183,000 shares of Common Stock on September 1, 2026. The sales were executed indirectly through the Alba 2003 Living Trust and Casa Alameda 2007, LLC at weighted average prices ranging from about $276.72 to $288.99 per share.
The trades occurred automatically pursuant to a Rule 10b5-1 trading plan adopted on May 22, 2026. After these transactions, Alba also reports indirect ownership of 5,000 shares through his spouse and direct ownership of 2,351 shares, while disclaiming beneficial ownership of the trust and LLC shares except for any pecuniary interest.
Astera Labs, Inc. (ALAB) received a notice that affiliate Stefan A. Dyckerhoff intends to sell up to 12,499 shares of common stock through Stifel Nicolaus & Company on NASDAQ, with an estimated aggregate market value of $3,436,755.00 as of the planned sale date of September 2, 2026. The notice states that 171,410,000 shares of common stock were outstanding. In the past three months, Dyckerhoff reported sales of 12,499 shares on July 1, 2026 and 12,499 shares on August 6, 2026.
Astera Labs, Inc. (ALAB) is the issuer for which a Form 144 notice has been filed covering a proposed resale of restricted/controlled shares. The filing states that the Mar 2011 Childrens Trust intends to sell up to 170,000 shares of common stock of Astera Labs through Morgan Stanley Smith Barney LLC, with a reported value of $50,486,600, to be sold on NASDAQ. These shares were acquired on 03/21/2018 in a private acquisition from the issuer and were paid for in cash. The notice also lists Rule 10b5-1 plan sales during the past three months by related accounts, including sales of 170,000, 33,000, and 150,000 Astera Labs common shares on 07/01/2026.
Astera Labs, Inc. (ALAB) received a notice that Alba 2003 Living Trust intends to sell up to 150,000 shares of its common stock under Rule 144 through Morgan Stanley Smith Barney LLC Executive Financial Services. The notice lists an aggregate market value of $44,547,000.00 for these shares, compared with 173,485,104 shares of common stock outstanding.
The shares to be sold were acquired on 03/21/2018 via a private acquisition from the issuer for cash. The filing also reports recent 10b5-1 sales during the past three months by related entities, including sales of 170,000, 33,000, and 150,000 ALAB common shares.